Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Название протокола

Клинические исследование Chronic Obstructive Pulmonary Disease: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo - Реестр клинических исследований

Платное

Нет

Дата начала и окончания КИ

2022-02-06 - 2022-02-06